Necrosulfonamide

Cat. # AG-CR1-3705

 

Product Details
Synonyms NSA; (2E)-N-[4-[[(3-Methoxy-2-pyrazinyl)amino]sulfonyl]phenyl]-3-(5-nitro-2-thienyl)-2-propenamide
Product Type Chemical
Properties
Formula

C18H15N5O6S2

MW 461.5
CAS 1360614-48-7
Purity Chemicals ≥95%
Appearance Off-white to yellow solid.
Solubility Soluble in DMSO (20mg/ml) or DMF (20mg/ml). Insoluble in water.
InChi Key FNPPHVLYVGMZMZ-XBXARRHUSA-N
Smiles O=C(/C=C/C1=CC=C([N+]([O-])=O)S1)NC2=CC=C(S(NC3=C(OC)N=CC=N3)(=O)=O)C=C2
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Protect from light.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.

Necrosulfonamide

    • Inhibitor of necroptosis, by blocking mixed lineage kinase domain-like protein (MLKL), a key substrate of receptor-interacting serine-threonine kinase 3 (RIP3). Shown to prevent the MLKL-RIP1-RIP3 necrosome complex from interacting with downstream necrosis effectors.
    • Potent inhibitor of gasdermin D that works well for mice studies. It binds directly to gasdermin D and inhibits the oligomerization of the N-terminus and therefore the pore formation and pyroptosis.
    • Displayed neuroprotective effects after ischemic brain injury, prevented cystine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells and rescued cells from TLR3 ligand-induced death.

    Product References

    Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase: L. Sun, et al.; Cell 148, 213 (2012)

    Necrosulfonamide inhibits necroptosis by selectively targeting the mixed lineage kinase domain-like protein: D. Liao, et al. Med. Chem. Commun. 5, 333 (2014)

    The degradation of mixed linage kinase domain-like protein promotes neuroprotection after ischemic brain injury: Y. Zhou, et al.; Oncotarget 8, 68393 (2017)

    CHAC1 degradation of glutathione enhances cysteine-starvation-induced necroptosis and ferroptosis in human triple negative breast cancer cells via the GCN2-elF2α-ATF4 pathway: M.S. Chen, et al.; Oncotarget 8, 114588 (2017)

    Activated platelets induce MLKL-driven neutrophil necroptosis and release of neutrophil extracellular traps in venous thrombosis: D. Nakazawa, et al.; Cell Death Discov. 5,(2018)

    Necrosulfonamide attenuates spinal cord injury via necroptosis inhibition: Y. Wang, et al.; World Neurosurg. 114, e1186 (2018)

    Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis: J.K. Rathkey, et al.; Sci. Immunol. 3, eaat2738 (2018)

    Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation: D. Cuchet-Lourenco, et al.; Science 361, 810 (2018)

  • Facebook - White Circle

© 2019 by Edward&Becky. Proudly created with Yao-Hong Biotechnology Inc.